on Theranexus (EPA:ALTHX)
Theranexus, CRNL and CERMEP winners of the Auvergne-Rhône-Alpes “Research Pact 2024” project
Theranexus, a biopharmaceutical company treating rare neurological diseases, the Lyon Neurosciences Research Center (CRNL) and CERMEP have been selected for the “2024 Research Pact” project in the Auvergne-Rhône-Alpes region. The project, named IMASO, will benefit from regional funding of €320,000.
This support is a continuation of the joint public/private NI2D laboratory. Created in 2020 in Lyon, this laboratory aims to improve the characterization of Theranexus drug candidates using preclinical neuroimaging tools. The IMASO project will make it possible to measure in vivo the cerebral distribution of antisense oligonucleotides (ASO) developed by Theranexus.
Mathieu Charvériat, CEO of Theranexus, expressed his gratitude to the region for its financial support, essential for the preclinical and clinical development of ASOs in various rare neurological diseases. Luc Zimmer, director of CERMEP and the BIORAN team at CRNL, also underlined their satisfaction at continuing this fruitful collaboration.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news